LONA:NASDAQ
LeonaBio Inc
5,75 US$
0,00%
(0,00) 1 d
5,73 US$
arrow_downward
−0,35% (−0,020)bedtimeEfter stängning
Stängd: 9 okt., 16:00:01 GMT−4 · USD
search
Alla symboler
| Symbol | Pris | Ändring | Ändring i procent |
|---|
insights_autoGenererar de viktigaste insikterna för LONA …
Öppen
5,82 US$
Högt
6,10 US$
Lågt
5,56 US$
Börsvärde
54,17 mn
Genomsn. vol.
341,74 tn
Volym
66,68 tn
52v högst
14,19 US$
52v lägst
2,21 US$
EPS
−19,72 US$
Beta
2,11
Utestående aktier
9,42 mn
Antal anställda
19
Öppen
5,82 US$
Högt
6,10 US$
Lågt
5,56 US$
Börsvärde
54,17 mn
Genomsn. vol.
341,74 tn
Volym
66,68 tn
52v högst
14,19 US$
52v lägst
2,21 US$
EPS
−19,72 US$
Beta
2,11
Utestående aktier
9,42 mn
Antal anställda
19
Nyheter och artiklar
Från webbkällor och nyhetspartner
Invezz
·
för 3 dagar sedan
Dow håller sig stabilt medan Nasdaq sjunker 1,24 % på AI-aktier och oljeuppgång
StreetInsider
·
för 26 minuter sedan
XRP News Today: Nasdaq Exposure Could Transform XRP as Remittix Targets Everyday Payment Adoption
Mitrade
·
för 10 minuter sedan
XRP’s Nasdaq Moment Nears: 5 Things to Know About Evernorth
Bloomberg.com
·
för 3 timmar sedan
Oil Rises on Mideast Attacks, Dollar Edges Higher: Markets Wrap
Profil
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Om LeonaBio Inc